Filing Flows › Comparisons › OCUL vs APMD
Ocular Therapeutix vs Apnimed: OCUL and APMD compared
Ocular Therapeutix is the larger company: $12.9M of revenue in its latest quarter (Q3 2026) against $12.1M for Apnimed (Q2 2026). Ocular Therapeutix is growing faster (-12% against -29% a year earlier). Apnimed is more profitable, with an operating margin of -96.9% against -760.1%.
Where the money goes: OCUL and APMD
Ocular Therapeutix (OCUL) · Q3 2026
Ocular Therapeutix, Q3 2026: revenue $12.9M (-12% year over year), operating margin -760.1%, net loss $94.8M, operating cash flow −$65.6M. The chart follows the revenue to costs, profit and cash.
Apnimed (APMD) · Q2 2026
Apnimed, Q2 2026: revenue $12.1M (-29% year over year), operating margin -96.9%, net earnings $126M. The chart follows the revenue to costs, profit and cash.
| Ocular Therapeutix (OCUL) | Apnimed (APMD) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $12.9M | $12.1M |
| Revenue growth, Y/Y | -12% | -29% |
| Operating margin | -760.1% | -96.9% |
| Net earnings | −$94.8M | $126M |
| Net margin | -736.2% | — |
| Operating cash flow | −$65.6M | — |
Questions
Which is bigger, Ocular Therapeutix or Apnimed?
Ocular Therapeutix is the larger company: $12.9M of revenue in its latest quarter (Q3 2026) against $12.1M for Apnimed (Q2 2026).
Is Ocular Therapeutix or Apnimed growing faster?
Ocular Therapeutix is growing faster (-12% against -29% a year earlier).
Which is more profitable, Ocular Therapeutix or Apnimed?
Apnimed is more profitable, with an operating margin of -96.9% against -760.1%.
More: Ocular Therapeutix earnings · how Ocular Therapeutix makes money · Apnimed earnings · how Apnimed makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Sep 8, 2026). Fiscal quarters can end on different dates. Not investment advice.